Reaching the base of the pyramid
As a global healthcare company with over 90 years of experience in innovation and leadership in diabetes care, Novo Nordisk has made a long-term commitment to improving access to treatment for people with diabetes.
Around one-third of the world’s population lacks regular access to healthcare, including essential medicines such as insulin.1 This is especially true in low- and middle-income countries, where the majority of people with diabetes live.
However, low- and middle-income countries account for only a small fraction of global healthcare spending on diabetes. As diabetes is often not a recognised healthcare priority, there are many barriers to accessing adequate care for those affected.
Novo Nordisk is the world’s largest producer of generic human insulin. It is therefore both a responsibility and a business opportunity for Novo Nordisk to support local health authorities in making sure that insulin reaches those who need it.
The Base of the Pyramid (BoP) project, which forms part of Novo Nordisk’s renewed strategy for global access to diabetes care, reflects the company’s commitment to making a positive contribution towards improving access to diabetes care and meeting the United Nations Sustainable Development Goals.